{"nctId":"NCT00642850","briefTitle":"STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients","startDateStruct":{"date":"2007-11"},"conditions":["Anemia"],"count":188,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: methoxy polyethylene glycol-epoetin beta [Mircera]"]}],"interventions":[{"name":"methoxy polyethylene glycol-epoetin beta [Mircera]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic renal anemia;\n* Continuous stable intravenous maintenance epoetin therapy during previous month;\n* Regular long-term hemodialysis therapy with the same mode of dialysis for previous 3 months.\n\nExclusion Criteria:\n\n* Transfusion of red blood cells during previous 2 months;\n* Poorly controlled hypertension, that is, sitting blood pressure exceeding 170/100 millimeter of mercury (mmHg) despite medication;\n* Significant acute or chronic bleeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Maintaining Average Hemoglobin Concentration Within +/-1 Gram Per Deciliter (g/dL) of Reference and Within the Target Range","description":"Percentage of participants maintaining their mean hemoglobin concentration in g/dL within plus or minus (+/-) 1 g/dL of their reference hemoglobin value, and between the target range of 10.0 and 12.0 g/dL during the efficacy evaluation period (EEP). The reference hemoglobin value was defined on the basis of the 5 assessments recorded during the Stability Verification Period (SVP) at Weeks -4, -3, -2, -1 and 0. The mean hemoglobin concentration for each individual participant during the EEP (Week 17 up to Week 24) was estimated as a time adjusted average.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin Concentration Between Reference (SVP) and EEP","description":"The mean change of the time adjusted average of hemoglobin from reference value obtained during the SVP (Week -4 up to Week -1) and the value during EEP (Week 17 up to Week 24) was assessed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Maintaining Hemoglobin Concentration Within the Target Range During EEP","description":"Percentage of participants maintaining hemoglobin concentration within the target range of 10.0 to 12.0 g/dL during EEP (Week 17 to Week 24) was assessed.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Time Spent by Participants With Hemoglobin Concentration in the Target Range During the EEP","description":"Mean time spent by participants with hemoglobin concentration in the target range of 10.0 to 12.0 g/dL during the EEP (Week 17 to Week 24) was assessed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":"18.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Any Dose Adjustment","description":"Percentage of participants requiring adjustment in the dose of study drug during the dose titration period (DTP: Week 1 to Week 16) and EEP (Week 17 to Week 24) was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Red Blood Cell Transfusion During the Study","description":"Number of participant who underwent red blood cell transfusion during the study was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-epoetin Antibody","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":188},"commonTop":["Hypertension","Diarrhoea","Bronchitis"]}}}